Terms: = Bone cancer AND FGFR1, CEK, 2260, ENSG00000077782, P11362, FLT2, CD331, H3, HBGFR, FGFBR, H5, KAL2, H2, BFGFR, N-SAM, H4 AND Treatment
179 results:
1. A high-content screen of FDA approved drugs to enhance CAR T cell function: ingenol-3-angelate improves B7-H3-CAR T cell activity by upregulating B7-H3 on the target cell surface via PKCα activation.
Lee HW; O'Reilly C; Beckett AN; Currier DG; Chen T; DeRenzo C
J Exp Clin Cancer Res; 2024 Apr; 43(1):97. PubMed ID: 38561833
[TBL] [Abstract] [Full Text] [Related]
2. bone Morphogenic Proteins in Pediatric Diffuse Midline Gliomas: How to Make New Out of Old?
Berthelot C; Huchedé P; Bertrand-Chapel A; Beuriat PA; Leblond P; Castets M
Int J Mol Sci; 2024 Mar; 25(6):. PubMed ID: 38542334
[TBL] [Abstract] [Full Text] [Related]
3. Establishment and characterization of two novel patient-derived cell lines from giant cell tumor of bone: NCC-GCTB8-C1 and NCC-GCTB9-C1.
Adachi Y; Noguchi R; Yoshimatsu Y; Sin Y; Osaki J; Ono T; Iwata S; Akiyama T; Tsuchiya R; Toda Y; Ishihara S; Ogura K; Kobayashi E; Kojima N; Yoshida A; Yokoo H; Kawai A; Kondo T
Hum Cell; 2024 May; 37(3):874-885. PubMed ID: 38466561
[TBL] [Abstract] [Full Text] [Related]
4. Feasibility and antitumour activity of the FGFR inhibitor erdafitnib in three paediatric CNS tumour patients.
Stepien N; Mayr L; Schmook MT; Raimann A; Dorfer C; Peyrl A; Azizi AA; Schramm K; Haberler C; Gojo J
Pediatr Blood Cancer; 2024 Mar; 71(3):e30836. PubMed ID: 38177074
[TBL] [Abstract] [Full Text] [Related]
5. FGF2 drives osteosarcoma metastasis through activating fgfr1-4 receptor pathway-mediated ICAM-1 expression.
Huang YC; Chen WC; Yu CL; Chang TK; I-Chin Wei A; Chang TM; Liu JF; Wang SW
Biochem Pharmacol; 2023 Dec; 218():115853. PubMed ID: 37832794
[TBL] [Abstract] [Full Text] [Related]
6. Highly proliferative and hypodifferentiated CAR-T cells targeting B7-H3 enhance antitumor activity against ovarian and triple-negative breast cancers.
Zhang X; Guo H; Chen J; Xu C; Wang L; Ke Y; Gao Y; Zhang B; Zhu J
Cancer Lett; 2023 Sep; 572():216355. PubMed ID: 37597651
[TBL] [Abstract] [Full Text] [Related]
7. Erdafitinib in patients with advanced solid tumours with FGFR alterations (RAGNAR): an international, single-arm, phase 2 study.
Pant S; Schuler M; Iyer G; Witt O; Doi T; Qin S; Tabernero J; Reardon DA; Massard C; Minchom A; Lugowska I; Carranza O; Arnold D; Gutierrez M; Winter H; Stuyckens K; Crow L; Najmi S; Hammond C; Thomas S; Santiago-Walker A; Triantos S; Sweiti H; Loriot Y;
Lancet Oncol; 2023 Aug; 24(8):925-935. PubMed ID: 37541273
[TBL] [Abstract] [Full Text] [Related]
8. Targeting BRPF3 moderately reverses olaparib resistance in high grade serous ovarian carcinoma.
Bitler BG; Bailey CA; Yamamoto TM; McMellen A; Kim H; Watson ZL
Mol Carcinog; 2023 Nov; 62(11):1717-1730. PubMed ID: 37493106
[TBL] [Abstract] [Full Text] [Related]
9. Establishment and characterization of two novel patient-derived cell lines from giant cell tumor of bone.
Ono T; Noguchi R; Yoshimatsu Y; Sin Y; Tsuchiya R; Akiyama T; Kojima N; Toda Y; Sato C; Fukushima S; Yoshida A; Kawai A; Kondo T
Hum Cell; 2023 Sep; 36(5):1804-1812. PubMed ID: 37328637
[TBL] [Abstract] [Full Text] [Related]
10. Switchable CAR T cell strategy against osteosarcoma.
Hidalgo L; Somovilla-Crespo B; Garcia-Rodriguez P; Morales-Molina A; Rodriguez-Milla MA; Garcia-Castro J
Cancer Immunol Immunother; 2023 Aug; 72(8):2623-2633. PubMed ID: 37062034
[TBL] [Abstract] [Full Text] [Related]
11. RhRu Alloy-Anchored MXene Nanozyme for Synergistic Osteosarcoma Therapy.
Liang Y; Liao C; Guo X; Li G; Yang X; Yu J; Zhong J; Xie Y; Zheng L; Zhao J
Small; 2023 Jun; 19(22):e2205511. PubMed ID: 36871143
[TBL] [Abstract] [Full Text] [Related]
12. NIR Responsive Doxorubicin-Loaded Hollow Copper Ferrite @ Polydopamine for Synergistic Chemodynamic/Photothermal/Chemo-Therapy.
Chu X; Zhang L; Li Y; He Y; Zhang Y; Du C
Small; 2023 Feb; 19(7):e2205414. PubMed ID: 36504423
[TBL] [Abstract] [Full Text] [Related]
13. Collaborative Design of MgO/FeO
Zhang D; Tan J; Xu R; Du H; Xie J; Peng F; Liu X
Small; 2023 Feb; 19(5):e2204852. PubMed ID: 36464630
[TBL] [Abstract] [Full Text] [Related]
14. Tumor-induced Osteomalacia: A Comprehensive Review.
Minisola S; Fukumoto S; Xia W; Corsi A; Colangelo L; Scillitani A; Pepe J; Cipriani C; Thakker RV
Endocr Rev; 2023 Mar; 44(2):323-353. PubMed ID: 36327295
[TBL] [Abstract] [Full Text] [Related]
15. B7-H3 targeted CAR-T cells show highly efficient anti-tumor function against osteosarcoma both in vitro and in vivo.
Zhang Q; Zhang Z; Liu G; Li D; Gu Z; Zhang L; Pan Y; Cui X; Wang L; Liu G; Tian X; Zhang Z
BMC Cancer; 2022 Nov; 22(1):1124. PubMed ID: 36320072
[TBL] [Abstract] [Full Text] [Related]
16. B7-H3-targeting Fc-optimized antibody for induction of NK cell reactivity against sarcoma.
Hagelstein I; Engel M; Hinterleitner C; Manz T; Märklin M; Jung G; Salih HR; Zekri L
Front Immunol; 2022; 13():1002898. PubMed ID: 36275693
[TBL] [Abstract] [Full Text] [Related]
17. NIR-II Excitation Phototheranostic Platform for Synergistic Photothermal Therapy/Chemotherapy/Chemodynamic Therapy of Breast cancer bone Metastases.
Sun P; Qu F; Zhang C; Cheng P; Li X; Shen Q; Li D; Fan Q
Adv Sci (Weinh); 2022 Nov; 9(33):e2204718. PubMed ID: 36216756
[TBL] [Abstract] [Full Text] [Related]
18. Aberrant paracrine signalling for bone remodelling underlies the mutant histone-driven giant cell tumour of bone.
Cottone L; Ligammari L; Lee HM; Knowles HJ; Henderson S; Bianco S; Davies C; Strauss S; Amary F; Leite AP; Tirabosco R; Haendler K; Schultze JL; Herrero J; O'Donnell P; Grigoriadis AE; Salomoni P; Flanagan AM
Cell Death Differ; 2022 Dec; 29(12):2459-2471. PubMed ID: 36138226
[TBL] [Abstract] [Full Text] [Related]
19. Osteosarcoma with cell-cycle and fibroblast growth factor genomic alterations: case report of Molecular Tumor Board combination strategy resulting in long-term exceptional response.
Persha HE; Kato S; De P; Adashek JJ; Sicklick JK; Subbiah V; Kurzrock R
J Hematol Oncol; 2022 Aug; 15(1):119. PubMed ID: 36031605
[TBL] [Abstract] [Full Text] [Related]
20. A truncated derivative of fgfr1 kinase cooperates with FLT3 and KIT to transform hematopoietic stem cells in syndromic and de novo AML.
Cai B; Liu Y; Chong Y; Mori SF; Matsunaga A; Zhang H; Fang X; Chang CS; Cowell JK; Hu T
Mol Cancer; 2022 Jul; 21(1):156. PubMed ID: 35906694
[TBL] [Abstract] [Full Text] [Related]
[Next]
